SS Innovations International Inc. filings document a Nasdaq-listed surgical robotics issuer and its formal disclosures around the SSi Mantra platform. Recent Current Reports on Form 8-K record product and regulatory updates, telesurgery announcements, conference-related disclosures, financial-results releases and Regulation FD communications.
The filing record also covers capital structure events, including an unregistered private placement of common stock, and identifies the company’s common stock as registered on Nasdaq under SSII. Annual-report and current-report disclosures provide formal context for operating results, product development, clinical and regulatory timelines, forward-looking statements, and the company’s subsidiary-based reporting perimeter.
SS Innovations International, Inc. furnished its updated October 2026 company presentation for communications with shareholders and the investment community. It describes the SSi Mantra surgical-robotics platform and reports 244 systems installed and 14,503 multi-specialty surgeries as of September 28, 2026; the installed base spans 12 countries.
Revenue was $42,484,747 in 2025, compared with $20,649,528 in 2024; for the six months ended June 30, 2026, revenue was $25,041,075, compared with $15,120,915 a year earlier. For those six-month periods, gross margin was 49.6%, versus 46.3%, while net loss was $6,243,921, versus $5,938,044. Cash at June 30, 2026 was $22,295,891, including $8,648,461 of restricted cash.
As of September 28, 2026, 195 telesurgeries had been completed with the SSi Mantra; the presentation states India generated approximately 87% of 2025 revenue.
SS Innovations International, Inc. (SSII) reported a corporate update describing continuing progress and milestones for its SSi Mantra surgical robotic platform. The update highlights advances in global expansion, pediatric robotic surgery, robotic telesurgery, and growing installations, procedures, and system utilization.
The company develops the SSi Mantra robotic system and complementary SSi Mudra instruments aimed at making robotic surgery more affordable and accessible worldwide. SSi Mantra is described as a user-friendly, modular, multi-arm system with advanced visualization and tele-surgeon capabilities, and has been clinically validated in India across more than 170 different types of surgical procedures, including cardiac and pediatric surgeries.
SS Innovations International, Inc. (SSII) reported that Chairman, CEO and major shareholder Sudhir Srivastava, through entity Sushruta Pvt. Ltd., sold 33,333 shares of common stock on September 4, 2026 at $3.00 per share. Following this indirect sale, Sushruta Pvt. Ltd. held 108,520,928 shares of SSII common stock. No Rule 10b5-1 trading plan is reported for this transaction.
SS Innovations International, Inc. (SSII) reported a leadership change in its finance organization. Effective August 21, 2026, Sarah Romano is no longer serving as Chief Financial Officer of the company.
The company stated that Ms. Romano's departure was not due to any disagreement with SS Innovations on matters related to financial reporting, internal controls, operations, policies, or accounting practices.
SS Innovations International, Inc. insider Sudhir Srivastava, Chairman, CEO and more-than-10% owner, reported a bona fide gift transfer of 10,000 shares of common stock on 2026-08-14. The shares were held indirectly through Sushruta Pvt. Ltd., in which he has a controlling interest. After the gift, indirect holdings reported for this entity total 108,554,261 shares of common stock.
SS Innovations International, Inc. reported record second-quarter 2026 revenue of $13.9 million, up 39.4% from $10.0 million a year earlier, driven mainly by higher SSi Mantra system sales. First-half 2026 revenue was $25.0 million, an increase of 65.6% from $15.1 million in first-half 2025.
The company’s installed base expanded rapidly, with quarterly SSi Mantra installations rising from 23 to 30 and the cumulative installed base increasing from 105 to 224 systems. Quarterly SSi Mantra surgeries grew from 1,042 to 2,528, and cumulative surgeries from 4,657 to 12,272, indicating increased clinical utilization.
Despite strong top-line growth, SS Innovations recorded a net loss of $2.7 million for Q2 2026 versus a $0.3 million loss a year earlier, as operating expenses, including $2.2 million of stock-based compensation and higher R&D and SG&A, outweighed gross profit. For the first half of 2026, net loss was $6.2 million, similar to the prior year. Cash and cash equivalents increased to $22.7 million as of June 30, 2026, supported by a $18.4 million PIPE financing, while total assets reached $97.0 million and stockholders’ equity rose to $53.4 million.
SS Innovations International, Inc. reported strong top-line growth but continued losses for the three and six months ended June 30, 2026. Revenue for the quarter rose to $13.9 million from $10.0 million a year earlier, and six‑month revenue increased to $25.0 million from $15.1 million, driven mainly by higher system sales in India, which represented 93% of six‑month revenue.
Despite higher gross profit of $12.4 million for the first half, operating expenses grew to $18.3 million, including $5.3 million of stock‑based compensation and $3.4 million of research and development. The company posted a six‑month net loss of $6.2 million and total comprehensive loss of $8.2 million.
Liquidity improved after a March 2026 private placement that raised $18.4 million, contributing to cash, cash equivalents and restricted cash of $22.7 million at June 30, 2026 and a working capital surplus of $39.6 million. However, management states that existing cash and operating income are not expected to fund operations for the next 12 months, and explicitly notes substantial doubt about the company’s ability to continue as a going concern without additional financing or improved performance.
SS Innovations International, Inc. reports that CFO Sarah Romano holds options to purchase 750,000 shares of common stock, granted on August 3, 2026 at an exercise price of $3.95 per share and expiring on August 3, 2031.
The options vest 250,000 shares on August 3, 2027, then in 23 monthly installments of 20,833 shares and a final 20,841-share installment, subject to continued employment and immediate full vesting upon a qualifying Change in Control.
SS Innovations International, Inc. reported that its SSi Mantra surgical robotic system will be showcased at the 2026 Society of Robotic Surgery Annual Meeting in Hollywood, Florida on July 23-26, 2026. The system will be on display, featured in multiple breakout sessions, and used in a livestreamed kidney telesurgery partial nephrectomy between Gurugram and New Delhi, India. Chairman and CEO Dr. Sudhir Srivastava is scheduled to speak and participate in several sessions at the event.
As of July 6, 2026, cumulative multi-specialty procedures completed with the SSi Mantra totaled 12,375, including 653 cardiac procedures, 178 telesurgeries, and 225 pediatric surgeries. Approximately 2,100 physicians have been trained on the system, which has been used in over 170 different types of procedures.
SS Innovations International, Inc. appointed Sarah M. Romano as Chief Financial Officer, effective August 3, 2026, under a three-year employment agreement. The agreement provides an annual base salary of $440,000 plus eligibility for an annual performance-based cash bonus.
Romano will receive options under the 2026 Incentive Stock Plan to purchase 750,000 shares of common stock, vesting as to 250,000 shares on the first anniversary and then in 23 monthly installments of 20,833 shares and a final installment of 20,841 shares, subject to continued employment. The contract includes customary confidentiality, proprietary rights, non-competition and non-solicitation covenants and an indemnification agreement. Romano brings more than two decades of financial leadership experience in medical technology and life sciences companies and has helped raise over $100 million through public and private financings.